No abstract available
MeSH terms
-
Angiogenesis Inhibitors / metabolism
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / metabolism
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates / metabolism
-
Benzenesulfonates / pharmacology
-
Benzenesulfonates / therapeutic use*
-
Bevacizumab
-
Clinical Trials as Topic
-
Gastrointestinal Stromal Tumors / blood supply
-
Gastrointestinal Stromal Tumors / drug therapy
-
Humans
-
Kidney Neoplasms / blood supply
-
Kidney Neoplasms / drug therapy
-
Neoplasms / blood supply*
-
Neoplasms / drug therapy*
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyridines / metabolism
-
Pyridines / pharmacology
-
Pyridines / therapeutic use*
-
Sorafenib
-
United States
-
United States Food and Drug Administration
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates
-
Phenylurea Compounds
-
Pyridines
-
Vascular Endothelial Growth Factor A
-
Niacinamide
-
Bevacizumab
-
Sorafenib
-
Protein-Tyrosine Kinases